China Healthcare Sector Report 2020 2nd QuarterAn EMIS Insights Industry Report
EMIS is an ISI Emerging Markets Group Company Date: June 2020
Available in: English
In early 2020, a worldwide outbreak of coronavirus occurred, affecting the global socio-economic reality. COVID-19 posed a particular challenge to the healthcare industry. Since the pandemic started in Wuhan, Hubei province, China took a leading role in the fight against the virus, providing guidelines and support to the other countries affected by COVID-19 at a later stage. Apart from the traditional methods in this emergency situation, i.e. physical treatment at hospitals and medical facilities, a complementary and innovative new approach was widely incorporated into China’s healthcare system – the internet-based healthcare. Leading industry players, including Alibaba’s AliHealth, Ping An’s Good Doctor and Tencent-backed WeDoctor platforms, all got engaged in providing online consultations and diagnosis, as well as psychological counseling during the pandemic. The cumulative number of visits to Ping An’s Good Doctor online platform, for instance, reached over 1.1bn from January 20 to February 10, 2020.
This report provides a complete and detailed analysis of the healthcare sector for China. EMIS Insights presents in-depth business intelligence in a standard format across countries and regions, providing a balanced mix between analysis and data.
What this report allows you to do:
- Understand the key elements at play in the healthcare sector in China
- Access forecasts for growth in the sector
- View key data on healthcare spending and health insurance in China
- Crystallise the forces both driving and restraining this sector in China
- Build a complete perspective on sector trade, investment and employment
- Understand the competitive landscape and who the major players are
- View M&A activity and major deals
- Gain an understanding of the regulatory environment for the sector in China
- Build a clear picture of trends and issues for sub-sectors (e.g. medical institutions, medical devices and pharmaceuticals).
See below for a complete table of report contents: